Page last updated: 2024-09-04

cyc 202 and Leukemia

cyc 202 has been researched along with Leukemia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andera, L; Beranova, L; Bohmova, M; Gasova, Z; Ivanek, R; Klanova, M; Klener, P; Koc, M; Ludvikova, Z; Molinsky, J; Necas, E; Strnad, M; Trneny, M; Zivny, J1
Conrad, D; Dai, Y; Dent, P; Grant, S; Krystal, G; Rahmani, M; Yu, C1
Almenara, JA; Atadja, P; Craig, R; Dent, P; Grant, S; Maggio, SC; Rosato, RR; Vrana, J1
Chen, S; Dai, Y; Dent, P; Grant, S; Harada, H1

Other Studies

4 other study(ies) available for cyc 202 and Leukemia

ArticleYear
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Death Domain Receptor Signaling Adaptor Proteins; Fas Ligand Protein; Humans; Leukemia; Lymphoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2013
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Cancer research, 2003, Apr-15, Volume: 63, Issue:8

    Topics: 2-Aminopurine; Antineoplastic Agents; Apoptosis; Chromones; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Leukemia; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Roscovitine; Tumor Cells, Cultured

2003
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Cytosol; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Jurkat Cells; Leukemia; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Time Factors; U937 Cells; X-Linked Inhibitor of Apoptosis Protein

2005
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cyclin-Dependent Kinases; Down-Regulation; Drug Synergism; HL-60 Cells; Humans; Jurkat Cells; Leukemia; Mice; Mice, Knockout; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; RNA Interference; Roscovitine; Sulfonamides; U937 Cells

2007